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Abstract 
Patients with hypersomnia disorders (HD) suffer from debilitating symptoms that result 
in reduced functioning, depression, anxiety, and overall worse quality of life. Little is 
known about the need and desire of this population to utilize Behavioral Sleep Medicine 
(BSM) interventions that focus on psychosocial functioning and quality of life, and there 
have been limited attempts to develop such interventions. The purpose of this survey 
study was to gather patient-centered data on engagement in pharmacological and non-
pharmacological interventions, the psychosocial impact of HD symptoms on quality of 
life and mental health, and potential interest in BSM services, such as cognitive 
behavioral therapy, mindfulness/yoga, and support groups. We obtained responses from 
371 individuals with HD (65.2% narcolepsy and 34.8% idiopathic hypersomnia) to an 
internet-based survey. Overall, HD patients reported engagement in pharmacological and 
non-pharmacological interventions, with narcolepsy patients reporting more perceived 
effectiveness than those with idiopathic hypersomnia.  In addition, HD patients reported a 
strong negative impact on psychosocial functioning, with elevations in depression and 
anxiety symptoms along with significant impact on functioning and quality of life. The 
majority (71.7-85.5%) voiced at least some interest in BSM services. These data suggest 
that there is substantial interest and need for BSM services that focus on assessment and 
treatment of psychosocial functioning related to HD.  
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Introduction 
Hypersomnia Disorders (HD) of central origin includes narcolepsy and idiopathic 
hypersomnia (also called hypersomnolence disorder).  These disorders share the core 
feature of excessive daytime sleepiness (EDS) that occurs on a frequent and persistent 
basis despite adequate total sleep time and are not attributable to other causes (American 
Psychiatric Association, 2013).  Currently, there is no cure for HD and thus the goal of 
treatment is symptomatic control, primarily targeting the symptom of EDS 
(Guilleminault & Cao, 2011; Morgenthaler et al., 2007).  Pharmacological approaches are 
considered the first line treatment. Practice parameters for the treatment of HD by the 
American Academy of Sleep Medicine concluded that modafinil, amphetamine, 
methamphetamine, dextroamphetamine, and methylphenidate have sufficient evidence 
for effectiveness and are appropriate for use in treatment of EDS in HD (Morgenthaler et 
al., 2007).  
In addition to pharmacotherapy, non-pharmacological strategies are commonly 
used to manage EDS, either as an adjunct to medication or as an alternative treatment.  
As medications alone may not completely resolve EDS, less than 15% of patients with 
narcolepsy rely on medications alone (Alaia, 1992) and up to 54% of these patients rely 
exclusively on behavioral strategies (Bruck & Broughton, 2001; Cohen, Nehring, & 
Cloninger, 1996; Daniels, King, Smith, & Shneerson, 2001; Rogers, 1984).  Common 
behavioral approaches that are used by patients to manage EDS include scheduled 
daytime naps, sleep hygiene, dietary manipulations, and physical activity (Cohen et al., 
1996; Conroy, Novick, & Swanson, 2012).  Patients with narcolepsy also identified 
environmental manipulations (e.g., avoid hot rooms, keep room cool, seek fresh air), 
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engagement or disengagement in activities (e.g., be active in conversations, avoid ‘boring’ 
events, restrict evening events) and different physical (e.g., pinch self, clench teeth) and 
emotional techniques (e.g., avoid emotional experiences, excitement) for management of 
symptoms (Cohen et al., 1996).  However, there are limited data on HD patient’s 
perceived ratings of effectiveness and where they learn these non-pharmacological 
interventions for EDS. 
Although EDS is the primary symptom of HD, the consequences of these 
conditions extend beyond the effects of sleepiness and the deleterious impact on 
psychosocial factors and quality of life has been well documented (Bruck & Broughton, 
2001; Daniels et al., 2001; Dodel et al., 2007; Jennum, Ibsen, Avlund, & Kjellberg, 2014; 
Ozaki et al., 2012; Rogers, 1984; Vignatelli et al., 2004; Vignatelli, Plazzi, Peschechera, 
Delaj, & D’Alessandro, 2011).  Patients with HD have more educational problems, 
behavioral problems, show higher rates of depression, anxiety, experience more 
challenges at work, and are more prone to driving accidents (Daniels et al., 2001; 
Dauvilliers, Lopez, Ohayon, & Bayard, 2013; Dodel et al., 2007; Douglas, 1998; Stores, 
Montgomery, & Wiggs, 2006; Vernet & Arnulf, 2009).  While treatments for HD have 
been aimed at improving EDS, there is virtually no literature on treatments aimed at 
addressing emotional or psychosocial functioning related to EDS.  In a recent systematic 
review evaluating the literature on non-pharmacological strategies for narcolepsy 
(Neikrug & Ong, in press), we observed that the majority of studies were conducted over 
14-39 years ago and only one study assessed for psychiatric symptoms as an outcome and 
no study evaluated quality of life.  We also found no study of cognitive strategies, 
educational interventions, or multi-component therapy that address psychosocial 
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functioning or coping with the impact of HD symptoms.  Instead, the majority of research 
has focused on the effect of behavioral strategies to reduce EDS (e.g., scheduled daytime 
naps).  Given that patients with HD carry a heavy disease burden and chronic EDS has 
such a deleterious effect on the quality of life, there is a major gap in the literature on 
formal interventions aimed at improving psychosocial functioning and quality of life in 
HD patients.  
Behavioral sleep medicine (BSM) is a rising specialty that focuses on cognitive, 
behavioral and emotion-focused approaches in the prevention and treatment of sleep 
disorders.  Within BSM, cognitive-behavioral therapy for insomnia (CBTI) has gained 
prominence as an empirically supported treatment for chronic insomnia (Merrigan, 
Buysse, Bird, & Livingston, 2013).  However, far less attention has been given to the 
systematic development and testing of formal BSM interventions aimed at disorders of 
chronic EDS.  Currently, there is no specific data to indicate that BSM services are 
needed for patients with HD and it is not known if patients with HD would be interested 
in BSM services, such as a cognitive-behavior therapy, to aid in symptom management 
and psychosocial functioning.   
The aim of this study was to evaluate the concept viability of developing formal 
BSM services for patients with HD.  Using a population-based survey, we sought to 
gather patient-centered data to characterize patient engagement in pharmacological and 
non-pharmacological interventions, the psychosocial impact of HD, and patient interest in 
formal BSM services, such as cognitive behavioral therapy, mindfulness/yoga, and 
support groups.  We hypothesized that: 1) Both pharmacological and non-
pharmacological approaches are highly used by HD patients, 2) HD patients experience 
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elevations on symptoms of depression and anxiety, and 3) HD patients would endorse 
interest in formal BSM services, including CBT, support groups, and mindfulness-based 
approaches.   
Methods 
Design Considerations  
This study was initiated to serve as a starting point for developing a BSM 
intervention for patients with HD.  Following Stage Ia of developing behavioral 
interventions, where the focus is on developing the elements needed to test the 
intervention (Rounsaville, Carroll, & Onken, 2001), the purpose of this study was to 
examine the concept viability of delivering BSM services to patients with HD.  Therefore, 
the overarching goal was to gather data on the need for cognitive and behavioral 
interventions, the potential treatment targets, and patient acceptability of these 
approaches.  We elected to use a population-based survey design to optimize 
generalizability and enhance representation of the population of people with HD.  To 
facilitate honest responses to potentially sensitive information (e.g., mental health 
symptoms), we did not collect identifiable information (i.e., name, location), maintaining 
patient anonymity.  These findings are intended to inform further treatment development 
activities (e.g., development of a treatment manual) with the eventual goal of conducting 
a pragmatic clinical trial.  We have outlined our process model of treatment development 
and testing in Figure 1. 
Survey Design 
 The survey was developed in multiple phases by the authors (ABN, JCO, and 
MRC) and was guided by the previous surveys conducted in narcolepsy patients (Cohen 
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et al., 1996; Rogers, 1984).  The survey was designed to be completed in less than 10-
minutes and therefore mainly included forced-choice multiple response questions, closed 
ended questions, and rating scales.  The survey included a total of 33 multi-itemed 
questions divided into several sections that asked about: diagnosis and disease symptoms, 
medication use and perceived effectiveness, behaviors and non-drug strategies for 
managing symptoms and their perceived effectiveness, mental health history, interest and 
experience in non-pharmacological interventions (e.g., cognitive-behavioral therapies, 
mindfulness meditation, yoga, and support groups), and demographics. Each section was 
presented with a brief explanation regarding the section.  This was an internet-based 
survey that was designed and distributed using SurveyMonkey©.  
Survey Procedures and Participants 
 To identify patients with HD we partnered with Wake Up Narcolepsy, a patient-
run organization.  The organization distributed the SurveyMonkey© link to members on 
their email listserv.  The survey was open for 29 days between August 8 and September 5, 
2014.  Two email notifications were sent by the organizations to their members the first 
on August 8 and the second on August 29.  The survey was anonymous in order to 
maximize honest reporting.  Survey respondents were provided with a brief written 
explanation of the survey and its purposes and all respondents had to agree to start the 
survey prior to seeing any additional content.  This study was reviewed and approved by 
the Institutional Review Board of Rush University Medical Center as an exempt study, as 
no protected health information or identifiers were collected.   
For this study, we included participants who were at least 17 years of age and 
self-reported a diagnosis of narcolepsy (Type I or Type II) or idiopathic hypersomnia.  
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Descriptive statistics including frequencies, means and standard deviations were 
generated for general description of the data.  Independent sample t-tests and Chi Square 
tests were conducted as post-hoc analyses to explore potential differences between 
diagnostic groups and gender.  Statistical analyses were performed using SPSS for Mac, 
version 21.0 (IBM Corp., 2012, Armonk, NY). 
Results  
A total of 518 survey responses were recorded. First, we screened the dataset for 
incomplete or unreliable data.  We excluded 3 duplicate responses (i.e., responses were 
identical with either exact time stamp or few minutes apart).  Additionally, we excluded 
50 respondents who did not respond past the first 4 survey questions (questions 1-3 
included agreement to participate, diagnosis, and types of non-pharmacological strategies 
utilized) as no data pertaining to our hypotheses were included in these questions.   
Second, from the remaining 465 survey responses, we excluded individuals who did not 
meet our study criteria.  We removed 38 responses that identified themselves as 
responding on behalf of someone else with either narcolepsy or idiopathic hypersomnia. 
We excluded one respondent who did not identify a diagnosis but completed the survey, 
seven participants that endorsed both having idiopathic hypersomnia and narcolepsy, and 
20 participants who reported not yet receiving a diagnosis.  Finally, we excluded 28 
respondents who were under the age of 17 or did not report age. The remaining 371 
respondents were included in the analyses. The majority (86.3%) identified as females 
and 12.7% as males.  Mean age was 37.1±11.1 (Range: 17-72).  Complete demographics 
are provided in Table 1. 
Patient Profile  
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Of the 371 respondents, 65.2% percent identified as having narcolepsy and  
34.8% as having idiopathic hypersomnia.  As expected, 97.6% of the respondents 
reported currently experiencing significant EDS.  Also expected is that cataplexy was 
reported by 66.1% of those with narcolepsy and none of those with idiopathic 
hypersomnia.  As seen in Table 2, those who identified as having narcolepsy reported 
more narcolepsy-related symptoms compared to those who identified as having idiopathic 
hypersomnia, suggesting the diagnosis was reported accurately and honestly.  The mean 
age of symptoms onset was 17.9±9.3 (Range: 0-57). 
Pharmacological Treatment 
The majority of respondents (83.3%) reported the use of medication to manage 
symptoms (Table 3). Use of stimulants were endorsed by 48%, modafinil/armodafinil 
were endorsed by 42%, sodium oxybate/γ-hydroxybutyric acid by 21%, and 
antidepressants were endorsed by 29% of the respondents.  There was a significant group 
difference in the use of sodium oxybate/γ-hydroxybutyric acid which was significantly 
more utilized by patients with narcolepsy (31% vs. 4%, p<0.001).  There were no 
significant differences between the groups or genders (Table 3).  Sixty nine percent of the 
respondents reported taking the medications daily and only 5% reported using the 
medication on three or less days per week.  Interestingly, 23% of the respondents 
reported that side effects from the medications have been preventing them from using the 
medications consistently with no significant differences between groups or gender.  
Medication effectiveness was rated by the entire sample as 6.0±1.8 on a 0-10 scale (0 
being not at all effective and 10 being most effective) and narcolepsy patients rated 
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medication as more effective compared to those with idiopathic hypersomnia (6.2±1.7 vs. 
5.4±1.9, p<0.001).  
Non-pharmacological strategies 
Respondents endorsed multiple non-pharmacological strategies/behaviors to help 
manage symptoms of the disease (Table 4a). Over 90% of the respondents reported using 
more than 1 strategy to manage symptoms, and daytime naps, scheduled nocturnal sleep, 
and caffeine emerged as the top 3 strategies.  Daytime napping was the strategy most 
commonly endorsed (86%), followed by scheduled nocturnal sleep (i.e., bedtime and 
wake uptime) (76%), and caffeine (76%).  Participants also reported use of exercise 
(57%), diet (50%), temperature manipulations (42%), chewing gum (30%), nicotine 
(23%), mindfulness (21%), and yoga (18%).  Use of diet as a strategy to manage 
symptoms was more commonly reported by patients with narcolepsy compared to 
patients with idiopathic hypersomnia (55% vs. 40%, p=0.004).  Other strategies that were 
reported by <5% of the respondents included Tai Chi, acupuncture, light therapy, energy 
drinks, poking themselves, flicking a rubber band on wrist, continual walking, eating ice, 
aroma therapy, use of different vitamins (e.g., B12, Vitamin C) and food supplements 
(e.g., iron, ginseng), music and brainwave apps, cognitive training, and massage therapy. 
Only 3.1% of the respondents reported that they do not use any non-pharmacological 
strategies.  No gender differences were found in reported strategies.  
While these strategies were widely used, the perceived effectiveness was 
generally rated poorly (Table 4b). Daytime napping received the highest rating of 
effectiveness of 4.3±2.8 out of a 0-10 scale (0 being not at all effective and 10 being most 
effective).  Daytime napping was followed by scheduled sleep and diet manipulation with 
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a rated effectiveness of 4.0.  Caffeine, nicotine, and exercise followed with ratings <4.0. 
We found that there were significant differences in these ratings between the diagnostic 
groups.  Except for nicotine, patients with narcolepsy reported significant higher 
effectiveness for all strategies (Table 4b).  
Respondents were also asked to endorse different ways in which they have 
learned about non-pharmacological strategies. Most responded learning strategies from 
non-professional sources (78% by trail and error, 44% by Internet, 38% from other 
patients, and 25% through patient-related organization).  Nonetheless, 33% reported that 
they were educated about non-pharmacological strategies by a sleep specialist and 24% 
by their primary physician.  
Mental Health and Psychosocial Impact  
 The respondents reported a negative impact on functioning and mental health.  In 
particular, cardinal symptoms of depression and anxiety were endorsed by 61-91% of 
individuals (Table 5) and only 4 participants with narcolepsy (1%) reported that they 
never experienced mood or anxiety symptoms as a result of their disease symptoms. 
Referrals to mental health specialists were also common and reported by 46% of the 
respondents.  The effectiveness of mental health interventions was rated as 5.0±3.2 on a 
0-10 scale (0 being not at all effective and 10 being most effective). There were no group 
or gender differences in referrals to mental health provider, or in effectiveness rating.  
Respondents reported that the disease symptoms have had a significant impact on 
their quality of life. When asked to rate the extent to which they have experienced 
difficulties in work/school, family relationships, and social relationship on a 0-10 scale (0 
being no difficulties and 10 being extreme difficulties), respondents rated experienced 
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difficulties generally high: difficulties in work and school were rated 8.4±1.8, difficulties 
with family relationships were rated 7.3±2.6, difficulties in social relationship were rated 
7.8±2.4. Additionally, participants reported that avoiding situations due to the symptoms 
of the disease resulted in significant difficulties in their lives (rated 7.2±2.5). There were 
no group or gender differences in these variables.  
Interest in BSM services 
The respondents endorsed overall high levels of interest in formal non-
pharmacological treatments that could be delivered as BSM services.  The majority 
(86%) voiced at least some interest in support groups, nearly two thirds (74%) endorsed 
interest in CBT, and 72% endorsed interest in mindfulness/yoga techniques (Table 6).  
When asked for the reasons for low or no interest in these services those respondents 
endorsed questionable effectiveness, having no time, and being satisfied with current 
medication regimen.  Participants were also asked to identify the type of professional 
they would feel more comfortable with for learning non-pharmacological strategies.  The 
majority (62%) indicated a preference for a BSM provider (i.e., psychologist, nurse, or 
psychiatrist with training in both mental health and sleep disorders), 23% preferred a 
physician specialized in sleep, 4% identified a mental health provider (i.e., psychologist, 
psychiatrist, or social worker), 4% identified their primary care provider, and 1% 
identified their nurse.   
Discussion  
 The main goal of this study was to gather patient-centered data on the importance, 
need, and interest in formal non-pharmacological BSM services for patients with HD.  
First, patient engagement for both pharmacological and non-pharmacological 
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interventions was high.  Eighty three percent of respondents reported the use of 
medication to manage HD symptoms with the most common medications being 
stimulants, followed by modafinil/armodafinil.  Furthermore, these medications were 
perceived to be relatively effective with an average rating of 6 out of 10 and 69% 
reported daily use, which is considerably higher than previous reports among narcolepsy 
patients (Rogers, Aldrich, Berrios, & Rosenberg, 1997; Rogers, Aldrich, & Lin, 2001). 
Patients with idiopathic hypersomnia reported lower (6.2 vs. 5.4) effectiveness scores for 
medications.  These findings indicate that HD patients are generally engaged in 
pharmacotherapy and perceive these as relatively effective, but with more perceived 
effectiveness by patients with narcolepsy.  
There was also high patient engagement for non-pharmacological interventions to 
manage EDS, with over 90% of the respondents reported using at least one non-
pharmacological strategy, such as daytime napping, caffeine, or a sleep schedule.  
However, these strategies were perceived to have low to moderate effectiveness (ranging 
from 1.9 to 4.3 out of 10) and patients with idiopathic hypersomnia consistently provided 
lower effectiveness rating to all strategies except for nicotine use.  Low effectiveness 
rating could be due to limited professional supervision or guidance for using these 
strategies.  Only 33% reported that they learned these strategies from a sleep specialist 
and 78% reported that they learned these strategies through trial and error, 44% via the 
Internet, and 38% from other patients.  Given the minimal professional oversight, it is 
unclear if these strategies were implemented correctly or systematically, which could 
amplify frustration with using these non-pharmacological techniques and cause patients 
to abandon these strategies prematurely.  It would seem that formal guidance from a sleep 
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physician or a BSM clinician is needed to evaluate the effectiveness of these behavioral 
strategies for managing EDS. 
Consistent with previous research, respondents reported high elevations on mental 
health symptoms and impaired psychosocial functioning.  Symptoms of depression and 
anxiety were extremely common, ranging from 61% to 91% with no significant 
differences between patients with narcolepsy and idiopathic hypersomnia.  The most 
prominent symptoms endorsed were difficulty with concentration (91%), irritability 
(87%), lost of interest (81%), and sad mood (81%).  Furthermore, referral to a mental 
health professional had only moderate effectiveness, rated as a 5 out of 10.  When asked 
about interest in BSM services that could address these mental health symptoms, patients 
were generally enthusiastic, with 62% of patients endorsing a preference to work with a 
BSM provider.  In terms of the type of service that could be used to address these 
psychosocial needs, 86% of patients expressed at least some interest in support groups, 
74% were interested in CBT, and 72% were interested in mindfulness/yoga.  These 
findings indicate that despite engagement in pharmacological and non-pharmacological 
treatments for EDS, both narcolepsy and idiopathic hypersomnia patients have severe 
impairments in psychosocial functioning.  Furthermore, they are enthusiastic about 
services such as support groups, CBT, and mindfulness-based approaches that could be 
used to improve psychosocial functioning and aid in coping with HD.  The majority of 
patients also favor a BSM provider to deliver these services.   
Study Limitations  
There are some limitations to this study. This was a population-based, anonymous, 
Internet survey study and therefore we were unable to confirm accuracy of the diagnoses 
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or responses.  Additionally, the survey was non-standardized and was not assessed for 
psychometric validity/reliability. While there were several standardized questionnaires 
that could have been used, these would have made the assessment significantly longer. 
We intentionally designed this survey to be brief to minimize burden and enhance 
participation since there was no compensation offered for completing the survey.  It is 
possible that the lack of standardized assessments or a trained interviewer may have 
resulted in biased or inaccurate responses.  Additionally, this study was not designed for 
group comparisons (by diagnosis and by gender) and due to the post-hoc and exploratory 
nature of these analyses further hypothesis-driven research using more rigorous methods 
should be conducted to confirm group differences observed in this study.  Nonetheless, 
the aim of this preliminary study was to evaluate the concept viability of BSM services 
for patients with HD.  As such, we felt that a survey study would allow us to gather data 
using a large sample at this stage of treatment development with future studies providing 
more rigorous testing and precision (see Figure 1). 
BSM Services in the Management of HD: Clinical Implications 
The findings from this survey point towards several possibilities for BSM services 
to be delivered to patients with HD.  One possibility is that a BSM clinician could 
provide formal guidance and oversight on behavioral interventions, such as scheduled 
naps and scheduled nighttime sleep to help manage EDS symptoms.  Prescribed 
scheduled naps have been shown to be effectiveness in improving alertness (Billiard, 
1976; Guilleminault, Stoohs, & Clerk, 1993; Helmus et al., 1997; Mullington & 
Broughton, 1993, 1994; Roehrs et al., 1986; Rogers & Aldrich, 1993; Rogers et al., 2001), 
especially for those who report high baseline levels of sleepiness (Rogers & Aldrich, 
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1993; Rogers et al., 2001).  Some patients might benefit from multiple short naps 
throughout the day (Godbout & Montplaisir, 1986; Mullington & Broughton, 1993; 
Rogers & Aldrich, 1993) while others might benefit from a single longer nap (Helmus et 
al., 1997).  Scheduled naps can also be combined with a structured and regular bedtime 
schedule, as tested by Rogers et al. (2001) to address nocturnal sleep disturbances, which 
were the second most commonly reported symptom in our survey.  The use of daytime 
sleep/wake diaries that specifically track daytime napping along with ratings systems of 
sleepiness/alertness could help determine specific napping and sleep schedules.  A second 
possibility is to develop interventions featuring education and cognitive skills targeting 
the mood/anxiety symptoms and psychosocial impairment that were revealed in this 
survey study.  Approaches such as Acceptance and Commitment Therapy (Hayes, 
Strosahl, & Wilson, 1999) or mindfulness-based therapies (e.g., Ong, Ulmer, & Manber, 
2012) may be appropriate to help patients shift from control of symptoms to management 
of symptoms while focusing on values and desired functioning.  Other techniques such as 
motivational interviewing, behavioral experiments, and relapse prevention could also be 
delivered by a BSM clinician (Kaplan & Harvey, 2009).  A third possibility is to combine 
these interventions into a formal multicomponent treatment package, similar to cognitive-
behavior therapy for insomnia.  At this time, there is insufficient evidence to consider 
these potential BSM services as an alternative to pharmacotherapy.  Instead, BSM 
clinicians should work together with a physician to optimize multidisciplinary care.  
Conclusion  
These findings support the concept viability for BSM services as an adjunctive or 
complementary treatment with pharmacotherapy for patients with HD.  In particular, 
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there is an unmet need to improve emotional and psychosocial functioning related to HD 
and patients reported enthusiasm for support groups, CBT, and mindfulness that are 
specifically aimed at improving emotional and psychosocial functioning.  In addition, 
BSM clinicians can provide formal guidance or supervision for implementing behavioral 
strategies to manage EDS.  Combining BSM services with pharmacotherapy could 
provide comprehensive care for patients with HD and significantly improve health-
related quality of life. 
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